Trial Profile
Post-Marketing Surveillance of Tecentriq in MFDS-Approved Indication(s)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 26 Aug 2022
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary)
- Indications Bladder cancer; Breast cancer; Liver cancer; Non-small cell lung cancer; Small cell lung cancer
- Focus Adverse reactions
- Sponsors Roche
- 23 Aug 2022 Status changed from active, no longer recruiting to completed.
- 08 Jun 2022 Status changed from recruiting to active, no longer recruiting.
- 03 Jun 2022 Planned End Date changed from 5 Aug 2023 to 5 Aug 2022.